Feed Preview

Alpha-Synuclein Structure and Function

Alpha-Synuclein Structure and Function diagram by StudioMolekuul, Shutterstock
StudioMolekuul, Shutterstock

α-Synuclein is an integral component of Lewy bodies which are comprised of protein clumps and are a pathological hallmark of Parkinson’s disease. Here is the latest research on α-Synuclein structure and function.

Top 20 most recent papers
Acta Neuropathologica

Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

Acta NeuropathologicaJanuary 20, 2020
Sven J van der LeeHenne Holstege
6
Nature Medicine

iPSC modeling of young-onset Parkinson's disease reveals a molecular signature of disease and novel therapeutic candidates

Nature MedicineJanuary 29, 2020
A H LaperleC N Svendsen
bioRxiv

Molecular dynamics simulation of local structural models of PrPSc reveals how codon 129 polymorphism affects propagation of PrPSc.

bioRxivDecember 27, 2019
Hiroki OtakiNoriyuki Nishida
2
Scientific Reports

The N-terminal Acetylation of α-Synuclein Changes the Affinity for Lipid Membranes but not the Structural Properties of the Bound State

Scientific ReportsJanuary 16, 2020
Matteo RunfolaGiuliana Fusco
5
1
bioRxiv

C subunit of the ATP synthase is an amyloidogenic channel-forming peptide: possible implications in mitochondrial pathogenesis

bioRxivJanuary 16, 2020
Giuseppe Federico AmodeoEvgeny V Pavlov
5
Scientific Reports

Design and Molecular dynamic Investigations of 7,8-Dihydroxyflavone Derivatives as Potential Neuroprotective Agents Against Alpha-synuclein

Scientific ReportsJanuary 19, 2020
Mohankumar ThangavelElangovan Namasivayam
1
1
The Journal of Immunology : Official Journal of the American Association of Immunologists

Size-Selective Phagocytic Clearance of Fibrillar α-Synuclein through Conformational Activation of Complement Receptor 4

The Journal of Immunology : Official Journal of the American Association of ImmunologistsJanuary 24, 2020
Kristian Juul-MadsenThomas Vorup-Jensen
2
Scientific Reports

Parkinson's disease recovery by GM1 oligosaccharide treatment in the B4galnt1+/- mouse model

Scientific ReportsDecember 20, 2019
Elena ChiricozziSandro Sonnino
1
1
Acta Neuropathologica

PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins

Acta NeuropathologicaDecember 20, 2019
Grant T CorbettDominic M Walsh
34
1
bioRxiv

Physical mechanisms of amyloid nucleation on fluid membranes

bioRxivDecember 27, 2019
Johannes KrausserAndela Saric
12
Translational Neurodegeneration

Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays

Translational NeurodegenerationJanuary 29, 2020
Niccolo CandeliseInga Zerr
bioRxiv

Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization

bioRxivJanuary 28, 2020
Antonio Dominguez-MeijideTiago Fleming Outeiro
Nature

Strain engineering and epitaxial stabilization of halide perovskites

NatureJanuary 10, 2020
Yimu ChenSheng Xu
6
9
2
2
The European Journal of Neuroscience

The contribution of Parkin, PINK1 and DJ-1 genes to selective neuronal degeneration in Parkinson's disease

The European Journal of NeuroscienceJanuary 29, 2020
Marc van der VlagPim R A Heckman
Neurology

Proteinopathy and longitudinal changes in functional connectivity networks in Parkinson disease

NeurologyDecember 20, 2019
Meghan C CampbellJoel S Perlmutter
22
1
1
Molecular Neurodegeneration

Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway

Molecular NeurodegenerationJanuary 15, 2020
Jae-Hyeon ParkPamela J McLean
7
1
Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society

The gut in Parkinson's disease: Bottom-up, top-down, or neither?

Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility SocietyDecember 20, 2019
Laurène Leclair-VisonneauThibaud Lebouvier
4
1
Molecular Therapy. Methods & Clinical Development

Non-toxic HSC Transplantation-Based Macrophage/Microglia-Mediated GDNF Delivery for Parkinson's Disease

Molecular Therapy. Methods & Clinical DevelopmentJanuary 1, 2020
Cang ChenSenlin Li
10
1
Aging

Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson's disease

AgingJanuary 15, 2020
Adeline Su Lyn NgEng-King Tan
2
1
ACS Omega

Fast and Quantitative Phospholipidomic Analysis of SH-SY5Y Neuroblastoma Cell Cultures Using Liquid Chromatography-Tandem Mass Spectrometry and 31 P Nuclear Magnetic Resonance

ACS OmegaDecember 24, 2019
Martin JakubecØyvind Halskau
1

See more papers from this feed

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Age-related Dementia

Age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. Evidence is reviewed that the neuropathology of the dementia is caused by the breakdown of small cerebral vessels (silent microbleeds), that the microbleeds result from pulse-induced damage to the cerebral vessels, and that pulse becomes increasingly destructive with age, because of the age-related stiffening of the aorta and great arteries, which causes an increase in the intensity of the pressure pulse. Discover the latest research on age-related dementia here.

© 2020 Meta ULC. All rights reserved
/feed-previews/alpha-synuclein-structure-and-function/a14f65a7-3296-44da-b665-d4480898b4bc